Latest Patents News

Page 1 of 104
Actinogen Medical’s pivotal XanaMIA trial produced a mixed result: Xanamem showed a small, non-significant benefit across the full 247-patient population, but a prespecified older-patient analysis found a statistically significant difference in disease stabilisation. The company will continue its open-label extension, suspend future Phase 3 spending and seek development partners.
Victor Sage
Victor Sage
19 Nov 2026
IPH has opened FY27 with an 8.4% revenue decline and a 13.4% fall in underlying EBITDA, with currency movements only partly explaining the weakness. New CEO Tony O’Malley says restoring organic growth in Australia and New Zealand is now a clear priority.
Victor Sage
Victor Sage
17 Nov 2026
Clover Corporation has entered FY27 with stronger margins, no interest-bearing debt and revenue momentum after reporting a 50% rise in FY26 NPAT. The company expects first-half FY27 revenue of about $60 million and says full-year revenue and earnings could outperform FY26 if current conditions persist.
Victor Sage
Victor Sage
17 Nov 2026
Moderna’s chief legal officer will retire in March under an agreement that provides US$1.63 million in fixed severance and up to US$8 million linked to litigation outcomes. The package also preserves her salary, benefits and equity vesting through her departure date.
Ada Torres
Ada Torres
14 Nov 2026
Cynata Therapeutics has lifted its proposed shareholder-approved placement to approximately $750,000, taking potential proceeds from its two-stage capital raising to about $1.663 million before costs. The biotech says key clinical and termination costs have been paid, while its externally funded kidney transplant trial remains in follow-up.
Ada Torres
Ada Torres
13 Nov 2026
Miro Sciences says Australia’s medicines regulator has completed its inspection of the manufacturing site for StemSmart, supporting the company’s planned Phase 2 Crohn’s disease trial. The inspection is a significant readiness step, but it is not itself approval to begin the study or confirmation of a successful audit outcome.
Ada Torres
Ada Torres
12 Nov 2026
Bayan Mining and Minerals has completed nine University of Queensland ion-exchange runs, recording an 11.2-fold peak increase in yttrium purity. The result strengthens the technical case for its licensed processing technology, but commercial feeds, recovery, costs and pilot performance remain untested.
Maxwell Dee
Maxwell Dee
12 Nov 2026
ION Video has secured a firm A$1 million investment from Priority Impact founder Magnus Rosengren ahead of key validation milestones for its video technology. The funding comes with 3.2 million options and lands before AWS proof-of-concept results and a potentially commercial phase 2 Nordic trial.
Sophie Babbage
Sophie Babbage
11 Nov 2026
Anson Resources says its proprietary pre-treatment process removed iron to undetectable levels from a third-party lithium brine in a single pass, while retaining lithium within its stated tolerance. The company is now discussing potential technology sales, although no transaction or financial benefit has been secured.
Maxwell Dee
Maxwell Dee
10 Nov 2026
EVE Health has signed a binding agreement giving it a 75% share of distributable profit from compounded men’s sexual health products in Australia. The capital-light arrangement preserves EVE’s intellectual property ownership, but provides no minimum volumes or guaranteed revenue.
Victor Sage
Victor Sage
10 Nov 2026
Clinuvel has outlined a multi-year expansion from peptide therapeutics into polymers, long-acting injectables, devices and digital health, backed by A$220 million of planned FY2027-FY2030 spending. The strategy comes with a near-term setback: first patient treatment in the CUV107 vitiligo study has been delayed to February 2027.
Victor Sage
Victor Sage
6 Nov 2026
Neuren has lifted its 2026 trofinetide income guidance to US$91 million-US$93 million after Acadia reported a 39% rise in Q3 DAYBUE sales and a US$35 million German launch milestone. Japan trial results also support a planned 2027 regulatory filing, although a launch remains subject to approval and a distribution partner.
Victor Sage
Victor Sage
5 Nov 2026

Browse the archive

Full archive